Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01585987 · ClinicalTrials.gov registry record · Phase 2

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

A Phase 2 study of Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
143
Enrollment target
20
Study locations

NCT01585987 is a Phase 2 study of Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 143 participants. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01585987, a Phase 2 study of Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
143 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.

Conditions Studied

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

Interventions

  • BIOLOGICAL Ipilimumab
  • OTHER Best Supportive care (BSC)

Study Locations (20)

Other

  • Local Institution - Montpellier
  • Local Institution - Nice
  • Local Institution - Rennes
  • Local Institution - Toulouse
  • Local Institution - Mainz
  • Local Institution - Hong Kong
  • Local Institution - Florence
  • Local Institution - Milan
  • Local Institution - Padua
  • Local Institution - Pisa
  • Local Institution - Roma

New York

  • Nyu Clinical Cancer Center - New York
  • Memorial Sloan Kettering Cancer Center - New York

Florida

  • Mount Sinai Medical Center - Miami Beach

Texas

  • The University Of Texas Md Anderson Cancer Center - Houston

Aichi-ken

  • Local Institution - Nagoya

Nagano

  • Local Institution - Saku-shi

Osaka

  • Local Institution - Osaka-sayama-shi

Saitama

  • Local Institution - Kitaadachi-gun

Trial Details

FieldValue
Enrollment Target 143 participants
Start Date 2012-07
Est. Completion 2015-04
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01585987

The ClinicalTrials.gov registry entry for NCT01585987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction appearing as the primary indexed condition, and to 2 interventions - of which Ipilimumab is the first listed.

NCT01585987 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT01585987 about?

NCT01585987 is a clinical study titled "An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy". The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.

What is the current status of trial NCT01585987?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2012-07. Estimated completion is 2015-04.

What conditions does trial NCT01585987 study?

This clinical trial studies the following conditions: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction.

What interventions are being tested in trial NCT01585987?

The interventions under investigation include: Ipilimumab (BIOLOGICAL), Best Supportive care (BSC) (OTHER).

Who is sponsoring clinical trial NCT01585987?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01585987 being conducted?

This trial has 20 study locations across Florida, New York, Texas, Aichi-ken, Nagano. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Explore more on PlainTrial

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.